(주)바이오 추가

SecurityACET / Adicet Bio, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership1,108,976 shares
Ownership 1.40%
Morgan Stanley ownership in ACET / Adicet Bio, Inc.

2024-07-10 - Morgan Stanley has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,108,976 shares of Adicet Bio, Inc. (US:ACET). This represents 1.4 percent ownership of the company. In their previous filing dated 2024-02-12 , Morgan Stanley had reported owning 2,777,725 shares, indicating a decrease of -60.08 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-07-10 2024-07-10 13G/A 2,777,725 1,108,976 -60.08 1.40 -78.12
2024-02-12 2024-02-12 13G 1,492,607 2,777,725 86.10 6.40 56.10
2020-02-13 2020-02-13 13G/A 3,214,730 1,492,607 -53.57 4.10 -53.41
2019-12-30 2019-12-30 13G 3,214,730 8.80

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ADICET BIO COM NEW 007002207 3,493 453 14.90 24 -8.00 0.0000
2026-05-27 2025-12-31 13F/A-1 ADICET BIO COM NEW 007002207 3,040 -13,777 -81.92 26 -30.56 0.0000
2026-02-13 2025-12-31 13F ADICET BIO COM NEW 007002207 3,040 -13,777 26 0.0000
2020-08-14 2020-06-30 13F RESTORBIO COM 76133L103 16,817 -824,949 -98.00 36 -95.85 0.0000
2020-05-26 2020-03-31 13F/A-1 RESTORBIO COM 76133L103 841,766 -650,841 -43.60 867 -61.02 0.0002
2020-05-15 2020-03-31 13F RESTORBIO COM 76133L103 841,766 -650,841 867 66.6037
2020-02-14 2019-12-31 13F RESTORBIO COM 76133L103 1,492,607 1,438,636 2,665.57 2,224 366.25 0.0005
2019-11-14 2019-09-30 13F RESTORBIO COM 76133L103 53,971 42,957 390.02 477 322.12 0.0001
2019-08-14 2019-06-30 13F RESTORBIO COM 76133L103 11,014 -17,304 -61.11 113 -41.45 0.0000
2019-05-15 2019-03-31 13F RESTORBIO COM 76133L103 28,318 -19,916 -41.29 193 -53.49 0.0001
2019-02-14 2018-12-31 13F RESTORBIO COM 76133L103 48,234 -14,428 -23.03 415 -56.22 0.0001
2019-04-23 2018-09-30 13F/A-2 RESTORBIO COM 76133L103 62,662 -25,234 -28.71 948 17.91 0.0002
2018-11-20 2018-09-30 13F/A-1 RESTORBIO COM 76133L103 62,662 0 948 0.0002
2018-11-14 2018-09-30 13F RESTORBIO COM 76133L103 62,662 -25,234 948
2019-04-23 2018-06-30 13F/A-1 RESTORBIO COM 76133L103 87,896 73,212 498.58 804 470.21 0.0002
2018-08-14 2018-06-30 13F RESTORBIO COM 76133L103 87,896 73,212 804
2019-04-23 2018-03-31 13F/A-1 RESTORBIO COM 76133L103 14,684 14,684 141 0.0000
2018-05-14 2018-03-31 13F RESTORBIO COM 76133L103 14,684 141 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.